p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding - PubMed (original) (raw)
. 1997 Sep 4;15(10):1179-89.
doi: 10.1038/sj.onc.1201459.
Affiliations
- PMID: 9294611
- DOI: 10.1038/sj.onc.1201459
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
C A Midgley et al. Oncogene. 1997.
Abstract
The tumour suppressor protein p53 is expressed at very low levels in normal cells but accumulates in response to DNA damaging agents such as u.v. irradiation. This increase is accompanied by transcriptional upregulation of the expression of a number of proteins including Mdm2 which can in turn inhibit p53 dependent transcriptional activation, creating a feedback loop resulting in down-regulation of p53 activity. Mutant p53 proteins are however frequently detected at constitutively high levels in many tumours and tumour cell lines, indeed this phenomenon has been used in several studies to diagnose p53 mutation in patient tumours. We show here that expression of mouse mutant p53 in tumour cell lines of this type results in high levels of both the endogenous p53 protein and the exogenously expressed mutant mouse protein, whereas the human tumour line MCF7 does not exhibit high levels of either endogenous human or exogenously expressed mouse mutant p53 unless stabilisation is induced by DNA damage. This suggests that the stability of mutant p53 is not intrinsic to mutant p53 protein structure but may vary in different cell backgrounds. We present evidence that p53 protein stability in tumour cell lines is determined by association with the Mdm2 tumour suppressor protein, and that p53 mutants which are unable to bind Mdm2 are stable in MCF7 cells. We propose that tumour lines which express high levels of transcriptionally inactive mutant p53 are unable to induce the expression of the Mdm2 protein which would normally provide a feedback mechanism down-regulating p53 protein levels in the absence of DNA damage signals. MCF7 cells however express a transcriptionally active p53 and retain the feedback regulation of p53 protein levels by Mdm2.
Similar articles
- Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation.
Hengstermann A, Whitaker NJ, Zimmer D, Zentgraf H, Scheffner M. Hengstermann A, et al. Oncogene. 1998 Dec 3;17(22):2933-41. doi: 10.1038/sj.onc.1202282. Oncogene. 1998. PMID: 9879999 - An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP. Midgley CA, et al. Oncogene. 2000 May 4;19(19):2312-23. doi: 10.1038/sj.onc.1203593. Oncogene. 2000. PMID: 10822382 - Mdm2 promotes the rapid degradation of p53.
Haupt Y, Maya R, Kazaz A, Oren M. Haupt Y, et al. Nature. 1997 May 15;387(6630):296-9. doi: 10.1038/387296a0. Nature. 1997. PMID: 9153395 - The p53 response to DNA damage.
Meek DW. Meek DW. DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1049-56. doi: 10.1016/j.dnarep.2004.03.027. DNA Repair (Amst). 2004. PMID: 15279792 Review. - Mdm2 in the response to radiation.
Perry ME. Perry ME. Mol Cancer Res. 2004 Jan;2(1):9-19. Mol Cancer Res. 2004. PMID: 14757841 Review.
Cited by
- Differential effect of plakoglobin in restoring the tumor suppressor activities of p53-R273H vs. p53-R175H mutants.
Lo CS, Alavi P, Bassey-Archibong B, Jahroudi N, Pasdar M. Lo CS, et al. PLoS One. 2024 Oct 3;19(10):e0306705. doi: 10.1371/journal.pone.0306705. eCollection 2024. PLoS One. 2024. PMID: 39361615 Free PMC article. - MDM2: current research status and prospects of tumor treatment.
Yao Y, Zhang Q, Li Z, Zhang H. Yao Y, et al. Cancer Cell Int. 2024 May 13;24(1):170. doi: 10.1186/s12935-024-03356-8. Cancer Cell Int. 2024. PMID: 38741108 Free PMC article. Review. - Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
Mehta H, Ambele MA, Mokgautsi N, Moela P. Mehta H, et al. Cells. 2024 Apr 18;13(8):700. doi: 10.3390/cells13080700. Cells. 2024. PMID: 38667315 Free PMC article. - The human adenovirus PI3K-Akt activator E4orf1 is targeted by the tumor suppressor p53.
Göttig L, Jummer S, Staehler L, Groitl P, Karimi M, Blanchette P, Kosulin K, Branton PE, Schreiner S. Göttig L, et al. J Virol. 2024 Apr 16;98(4):e0170123. doi: 10.1128/jvi.01701-23. Epub 2024 Mar 7. J Virol. 2024. PMID: 38451084 Free PMC article. - Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B, Yang P, Zhang S. Song B, et al. Cancer Commun (Lond). 2024 Mar;44(3):297-360. doi: 10.1002/cac2.12520. Epub 2024 Feb 4. Cancer Commun (Lond). 2024. PMID: 38311377 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous